Restless Leg Syndrome Medication Gambling
Side effects are a necessary evil when it comes to medication. Virtually any active medicine will have additional physical effects alongside the intended action of the substance, and these are usually relatively minor.
Physical side effects are usually tolerable, or may be managed using over-the-counter medicines or changes in lifestyle.
Restless legs syndrome (RLS) can lead to poor quality of life. Learn about treatments such as supplements, medication, foot wraps, and vibrating pads.
- Mild restless legs syndrome that isn't linked to an underlying health condition can be managed with just a few lifestyle changes. If symptoms are more severe, medication may be needed. Restless legs syndrome caused by an underlying health condition can often be cured by treating that condition.
- Drugs used to treat Restless Legs Syndrome The following list of medications are in some way related to, or used in the treatment of this condition. Select drug class All drug classes antiadrenergic agents, centrally acting (1) narcotic analgesics (1) benzodiazepines (1) benzodiazepine anticonvulsants (1) dopaminergic antiparkinsonism agents.
- Users stop using the medications or when the dose is lowered.” Dopamine Receptor Agonists (medications which treat Parkinson’s disease (PD) and Restless Leg Syndrome (RLS)) may lead to Disordered Gambling: Rotigotine-also known as Neupro (PD/RSL) Pergolide- also known as Permax and Prascend (PD).
However, sometimes the side effects of a drug can be damaging in a non-physical sense. In fact, pramipexole—a drug used for restless leg syndrome and Parkinson’s disease—may actually lead to hypersexuality or even compulsive gambling. The link has been previously documented, but the information hasn’t been disseminated widely enough to protect patients from the unintended effects.
How Pramipexole Ruined A Patient’s Life
Restless Leg Syndrome Medication Gambling Loss
Tuscaloosa News’ People’s Pharmacy segment gives citizens a chance to share their experience with medicines and have their problems addressed by an expert. Last month, the section received a question from a patient suffering from restless leg syndrome who also found him or herself compulsively shopping and gambling. The individual commented “This medication has ruined my life. I discovered only recently that the compulsive behaviors are drug side effects,” and drew attention to the fact that the symptoms of the original condition were getting worse, if anything.
In response, the expert shared additional stories from other patients with the same problem. Although pramipexole (brand name Mirapex) is the most well-known cause, other similar drugs such as ropinirole (Requip) can also lead to impulsive behavior.
How Pramipexole Leads to Compulsive Behaviors
Pramipexole is a dopamine-agonist drug, and many people will know that dopamine is the neurotransmitter implicated in most cases of addiction. It’s the brain’s “reward” chemical, but people suffering from Parkinson’s disease are deficient in it. A dopamine agonist basically tops up the body’s dopamine supply (albeit in a synthetic form), so for that reason alone there is reason to be concerned about its potential relationship with addictive behavior. The dosage for restless leg syndrome is much lower than that for Parkinson’s, so it’s expected that those taking the drug for Parkinson’s are at greater risk of compulsive behaviors.
Because of the link between pramipexole and the body’s dopamine system, the drug appears to have an impact on behavior. Patients who take the drug often report compulsive shopping, gambling, eating and sexual activity, which can understandably create many problems for the individual.
A Known Connection
Many studies have been conducted on the link between compulsive behavior and dopamine agonists, with the results showing that “impulse control disorders” are more common in both patients with Parkinson’s and restless leg syndrome who are receiving the drugs. A particularly large piece of research concluded that patients taking dopamine agonists are between two and three and a half times more likely to develop an impulse control disorder than those not taking them. The link isn’t fully understood, but it appears that the lower doses used in restless leg syndrome don’t remove the risk of developing compulsive behavior.
The role of the pharmaceutical companies has been questioned, with many high-profile lawsuits being filed related to the damaging side effects. According to some of these reports, the pharmaceutical companies were aware of the links between the drug and the conditions since the 1990s (when the link was revealed by a clinical trial), but they failed to take action to investigate the possibility further.
Additionally, the companies engaged in a marketing campaign targeted at physicians, which misrepresented the potential risks of the drugs. None of this type of behavior is particularly out of character for pharmaceutical companies—who are primarily concerned with selling pills, with serious side effects merely serving as a barrier to that goal—and the fact that the warning labels weren’t updated until 2005 shows the consequences this can have. The companies are now being ordered to make large payouts to account for the damages the drugs have caused.
What Should Patients Do?
Restless Leg Syndrome Medication Gambling
If you’re a patient taking a dopamine agonist like pramipexole, the options are unfortunately limited. It’s worth noting that the incidence of these side effects is quite low, but there is still a chance you’ll develop them. If you’re experiencing symptoms of compulsive behavior after starting on a dopamine agonist, the best thing to do is to contact your doctor about it as soon as possible. Compulsive gambling, sex and shopping all have the potential to financially ruin patients or obliterate romantic relationships, so the importance of reducing their impact can’t be overstated. In the event of negative consequences, your physician may be able to suggest an alternative treatment. Do what you can to better your health!
Tired of addiction calling the shots?
Addiction treatment changes lives. Call for a free benefits check.
- 877-671-1785
Brought to you by
DOPAMINE AGONISTS, ROPINIROLE AND PRAMIPEXOLE, ARE THE ONLY FDA-APPROVED RESTLESS LEGS SYNDROME (RLS) THERAPIES. AS SUCH, THESE TWO dopamine agonists are considered the first line of treatment (generally at low doses) for RLS in current evidenced-based guidelines. Dopamine agonists have long been used at higher doses to treat Parkinson disease (PD), and compulsive behaviors are well known to be associated with dopamine agonist use at these levels. In a small number of case reports, however, gambling has been observed in individuals with RLS who were treated on a low dose of dopamine agonists.– In addition, Ondo and Lai reported that of 89 RLS patients treated with dopamine agonists, 7 manifested compulsive shopping behaviors and 2 manifested gambling, though none were reported to manifest the compulsive eating reported in some PD cases. The authors noted that a failure to identify similar compulsive behavioral patterns among RLS and PD patients likely related more to the higher dopamine agonist treatment range in PD rather than to specific neurobiological etiologies underlying the two disorders. Thus, Ondo and Lai speculated that the potential for RLS patients to develop compulsive behaviors may be less noticeable given the smaller doses of dopamine agonists used to treat those patients.
Here, we describe a case of a 66-year-old woman with RLS diagnosed 14 years previously. She had been treated with levodopa, ropinirole, and pergolide at various times during the course of her RLS, without improvement in her symptoms. For 7 years she was successfully managed solely on pramipexole at a maximum dose of 0.25 mg daily, but eventually the patient’s symptoms grew more intense and began occurring earlier in the day. Her neurologist recommended she increase the pramipexole dose to 1.0 mg daily. After she had been on this dosage for one year without much improvement, she was referred to the RLS specialty team at our center for a second opinion.
After a thorough history and physical exam, it was concluded that this patient’s worsening symptoms were due to either disease progression or more likely, drug-induced augmentation. Due to strong suspicion of the latter, gabapentin was started with the goal of weaning off pramipexole. A few weeks later, she sent a letter describing the “change in her habits” that only became apparent after tapering the pramipexole (see excerpt). She also reported a conscious compulsion for nocturnal eating leading to a 9-pound weight gain while on pramipexole with a documented weight loss after stopping it. Interestingly, when initially seen in clinic, this patient did not report any compulsive behaviors despite being directly questioned about them. At a follow-up clinic visit, she reported feeling like her “normal self” and her husband stated he “has his old wife back after 7 years.”
DISCUSSION
Symptoms such as compulsive behaviors are evident in people with attention deficit hyperactivity disorder, which has been linked with RLS. Yet, in this report we describe a patient with RLS with no premorbid history of attention deficit disorder or compulsive behaviors, who began to demonstrate such behaviors only in relation to dopamine agonist administration. This case also highlights the lack of patient insight into her behaviors; she only became aware of her compulsive eating and shopping after she stopped the pramipexole. Furthermore, the pramipexole dose had been relatively low (0.25 mg per day) when the compulsive shopping began, a behavior that could be corroborated by the patient’s credit card records and her husband’s account of past events.
With a low dose of dopamine agonist, our patient’s compulsive behaviors, evident only in hindsight, were not as dramatic as the reports of excessive gambling or sexual urges reported for some patients with PD taking high doses of dopamine agonists. It would not be unusual, therefore, for subtle compulsive behaviors, such as those described in this case, to go undetected initially. Even the stronger compulsive behaviors of patients with PD taking dopamine agonists are not generally seen as a problem until the consequences, such as a major loss of money, call attention to the behaviors.
The descriptions of compulsive behaviors in the PD population have led some investigators to speculate whether the behaviors result from the neurodegenerative process of PD or represent a specific effect of dopamine agonists. Demonstration of such behavior in non-PD cases and at lower doses of dopamine agonist administration suggests that subtle compulsive behaviors may be more prevalent than previously recognized by patients and treating providers. This phenomenon, which has now been reported in the RLS population, may provide additional insight into the underlying etiology of compulsive behaviors and suggest a larger neuropharmacological role played by dopamine agonists.
While most neurologists may be familiar with RLS augmentation and simple progression of the disease, many may not be aware of the aberrant behaviors that may arise in the process of treating this condition with dopamine agonists. It might be worth considering use of compulsive behavior scales during dopamine agonist treatment for RLS patients to bring attention to and further understanding of the prevalence and degree of this problem within the RLS population.
Excerpt
“I heard an ad for Mirapex on TV and the word ‘compulsive’ was mentioned. Let me tell you about my problem and PLEASE keep this confidential. My husband does not know this. In the past few years I have been shopping compulsively and have now run my credit card debt up to over $40,000. Just recently, I have sat back and tried to examine why this happened. I never used to be this way. Since I started the new regimen with Neurontin I have also noticed that my behavior is not so compulsive and I am not reckless with my spending. In fact, I no longer have an interest in shopping.”
DISCLOSURE STATEMENT
This was not an industry supported study. Dr. Allen has received research support from GlaxoSmithKline and Sepracor; has consulted for GlaxoSmithKline, Boehringer Ingelheim, UCB, Xenoport, Sepracor, Novartis, Orion Pharma, Respironics, IM Systems, Pfizer, Jazz, and Schwarz Pharma; has participated in speaking engagements for Boehringer Ingelheim and GlaxoSmithKline; and has financial interests in IM Systems. Dr. Earley has received financial considerations for attendance of a meeting for Xenoport; has consulted for UCB; and has received honorarium from Boehringer Ingelheim for serving on a faculty for a symposium on RLS. Dr. Gamaldo has participated in a speaking engagement for Pfizer. Dr. Salas has indicated no financial conflicts of interest.
REFERENCES
